Navigation Links
Chimerix to Present at Upcoming Investor Conferences
Date:6/2/2010

RESEARCH TRIANGLE PARK, N.C., June 2 /PRNewswire/ -- Chimerix, Inc., a biotechnology company developing orally-available antiviral therapeutics, announced today that Kenneth I. Moch, President and Chief Executive Officer, will present at two upcoming investor conferences:  the 9th Annual Needham Healthcare Conference, 9:00 AM ET, June 9, 2010, and the Jefferies 2010 Global Life Sciences Conference, 12:45 PM ET, June 11, 2010. The conferences are being held in New York City.

Mr. Moch will provide a corporate overview, including an update on the company's clinical-stage candidates, CMX001 and CMX157.  CMX001 is an orally-available, broad-spectrum antiviral being developed for the treatment of dsDNA viral infections in immunocompromised patients.  The compound is in Phase 1 and 2 clinical trials for the treatment of cytomegalovirus and BK virus.  CMX157, a novel lipid conjugate of the drug tenofovir, was created to improve upon the efficacy and safety of the prodrug Viread®, the leading nucleoside reverse transcriptase inhibitor (NRTI) used in the treatment of HIV patients.  CMX157, which is in Phase 1 clinical trials, is being developed for its potential to reduce systemic toxicity and enable the development of one-pill once-a-day fixed dose anti-HIV combinations.

About Chimerix

Chimerix is developing antiviral therapeutics to treat life-threatening diseases.  Led by a world-class antiviral drug development team, Chimerix is advancing programs to address cytomegalovirus (CMV), BK virus, adenovirus, smallpox, human immunodeficiency virus (HIV), hepatitis C virus (HCV), respiratory syncytial virus (RSV) and influenza.  The company's lead compound, CMX001, is in Phase 1 and Phase 2 clinical studies for the treatment of BK virus and CMV, potentially deadly infections among immunocompromised patients.  CMX001 is also being developed as a biodefense countermeasure in the event of a smallpox release.  Chimerix has advanced a second antiviral compound, CMX157, into Phase 1 clinical studies.  CMX157 is being developed as a potential once-weekly nucleoside analogue against HIV infections.  Building on the company's extensive chemical library, Chimerix is also pursuing translational medicine efforts to address malaria, dengue fever and other public health needs.  Chimerix has received financing from leading venture capital firms, including Sanderling Ventures, Canaan Partners, Alta Partners, Asset Management Company and Frazier Healthcare Ventures, as well as significant funding from the National Institute of Allergy and Infectious Diseases.  Additional information about Chimerix and its antiviral drug development programs may be found online at http://www.chimerix.com.


'/>"/>
SOURCE Chimerix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Chimerix Initiates Phase 1 Study of CMX157
2. Chimerix Names George Painter, Ph.D., Chairman of the Board and Chief Scientific Officer; Appoints Kenneth I. Moch President and Chief Executive Officer
3. Chimerix Names Wendy Painter, M.D., M.P.H., as Chief Medical Officer
4. Chimerix, Inc. Appoints Kenneth I. Moch Chief Operating Officer
5. Chimerix Joins International Network of Organizations to Cure Malaria
6. Chimerix Completes Phase I Study and Initiates a Phase II Multi-dose Clinical Trial for CMX001
7. Merial to Screen Chimerix Chemical Library for Animal Health Drug Leads
8. Chimerix Appoints Neil Frazer, M.B., Ch.B., FRCA, FFPM as Chief Medical Officer
9. NeoGenomics to Present at Noble Financials 6th Annual Equity Conference on Monday, June 7th
10. China-Biotics to Present at Bank of America Merrill Lynch Healthcare Event on June 22
11. Merrimack Pharmaceuticals to Present at the Jefferies 2010 Global Life Sciences Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , ... June 23, 2016 , ... ... announced the launch of the Supplyframe Design Lab . Located in Pasadena, ... explore the future of how hardware projects are designed, built and brought to ...
(Date:6/23/2016)... BEACH, Calif. , June 23, 2016  Blueprint ... new biological discoveries to the medical community, has closed ... co-founder Matthew Nunez . "We have ... us with the capital we need to meet our ... will essentially provide us the runway to complete validation ...
(Date:6/23/2016)... ... June 23, 2016 , ... Regulatory Compliance Associates® ... provides a free webinar on Performing Quality Investigations: Getting to Root ... CT at no charge. , Incomplete investigations are still a major concern to ...
(Date:6/22/2016)... , June 22, 2016 Cell ... will allow them to produce up to one ... one lot within one week. These high-quality, consistent ... laboriously preparing cells and spend more time doing ... through a proprietary, high-volume manufacturing process that produces ...
Breaking Biology Technology:
(Date:5/16/2016)... , May 16, 2016   EyeLock LLC ... today announced the opening of an IoT Center of ... strengthen and expand the development of embedded iris biometric ... unprecedented level of convenience and security with unmatched biometric ... one,s identity aside from DNA. EyeLock,s platform uses video ...
(Date:5/3/2016)... Lithuania , May 3, 2016  Neurotechnology, ... released the MegaMatcher Automated Biometric Identification System ... of large-scale multi-biometric projects. MegaMatcher ABIS can process ... accuracy using any combination of fingerprint, face or ... MegaMatcher SDK and MegaMatcher Accelerator ...
(Date:4/26/2016)... and LONDON , ... Finacle, part of EdgeVerve Systems, a product subsidiary ... Onegini today announced a partnership to integrate the ...      (Logo: http://photos.prnewswire.com/prnh/20151104/283829LOGO ) ... provide their customers enhanced security to access and ...
Breaking Biology News(10 mins):